To assess the efficacy of intraperitoneal 0.25% levobupivacaine for postoperative analgesia following laparoscopic cholecystectomy

A prospective randomised double blinded controlled study to assess the efficacy of intraperitoneal 0.25% levobupivacaine for postoperative analgesia following laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020837

Enrollment

Registered

2019-08-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system

Interventions

Intervention1: 0.25% levobupivacaine: 30 ml Intraperitoneal 0.25% levobupivacaine is given before removal of the laparoscopic ports. Pain score(VAS) is assessed for first 24 hours is assessed. Time f

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing laparoscopic cholecystectomy Patients of ASA1 and ASA 2

Exclusion criteria

Exclusion criteria: Patients allergic to local anaesthetics Patients with severe cardiac, pulmonary, and neurological disease Patients in whom procedure has to be converted to open cholecystectomy Patients in whom abdominal drain will be kept Patients of weight less than 50 kg Patients not willing to participate

Design outcomes

Primary

Measure	Time frame
Time for the first request of analgesia within first 24 hoursTimepoint: Time for the first request of analgesia within first 24 hours	—

Secondary

Measure	Time frame
Post operative VAS score Total no. of analgesics used in first 24 hrsTimepoint: 24 hrs	—

Countries

India

Contacts

Public ContactPavithra Palaniappan

Sri Ramachandra institute of higher education and research

thames25@gmail.com9841552333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026